Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post–PCI in Patients With Atrial Fibrillation and Diabetes
Article 2019 en
Authors
MM
Michael Mæng
PS
Philippe Gabríel Steg
DB
Deepak L. Bhatt
Abstract
1 min read
In this subgroup analysis, dabigatran dual therapy had a lower risk for bleeding and a comparable rate of the efficacy endpoint compared with warfarin triple therapy in patients with atrial fibrillation with or without diabetes following percutaneous coronary intervention.
Christopher P. Cannon, Deepak L. Bhatt, Jonas Oldgren, Professor Gregory Lip, Stephen G. Ellis, Takeshi Kimura, Michael Mæng, Béla Merkely, Uwe Zeymer, Savion Gropper, Matias Nordaby, Eva Kleine, Ruth Harper, Jenny Manassie, James L. Januzzi, Jurriën M. ten Berg, Philippe Gabríel Steg, Stefan H. Hohnloser
Jonas Oldgren, Philippe Gabríel Steg, Stefan H. Hohnloser, Professor Gregory Lip, Stephen G. Ellis, Takeshi Kimura, Matias Nordaby, Jurriën M. ten Berg, Deepak L. Bhatt, Christopher P. Cannon, Eva Kleine
Jonas Oldgren, Philippe Gabríel Steg, Stefan H. Hohnloser, Professor Gregory Lip, Stephen G. Ellis, Takeshi Kimura, Matias Nordaby, Jurriën M. ten Berg, Deepak L. Bhatt, Christopher P. Cannon, Eva Kleine
Discussion(0)
No comments yet. Be the first to comment.